Values as of: 2024-11-17
COMMON STOCK | Health Information Services |
Last Closing
USD 24.6Change
0.00 (0.00)%Market Cap
USD 1.65BVolume
N/AAnalyst Target
N/AVerdict
Verdict
JMDC Inc. provides medical statistics data services in Japan. The company offers medical field big data services; life insurance field big data services; support services for health insurance associations and local government health services; health data platform; and medical institution support services. It serves health insurance unions, pharmaceutical companies, life and non-life insurance companies, research institutions, etc. JMDC Inc. was incorporated in 2002 and is headquartered in Tokyo, Japan. As of October 10, 2023, JMDC Inc. operates as a subsidiary of OMRON Corporation.
Company Website : https://www.jmdc.co.jp
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| L0T:F | GE HEALTHCARE TECH.INC. |
N/A |
USD 37.60B |
| 2HE:F | Healthequity Inc |
N/A |
USD 6.90B |
| 4YC:F | M3 INC. |
N/A |
USD 5.81B |
| 6HL0:F | R1 RCM Inc |
N/A |
USD 5.59B |
| OC9:F | Omnicell Inc |
N/A |
USD 2.04B |
| 1XZ:F | Ping An Healthcare and Technol.. |
N/A |
USD 2.03B |
| 1KJ:F | 10X GENOMICS DL -00001 |
N/A |
USD 1.73B |
| 9EH:F | Evolent Health Inc |
N/A |
USD 1.67B |
| 4LL:F | Teladoc Inc |
N/A |
USD 1.55B |
| 19P:F | Phreesia Inc |
N/A |
USD 1.22B |
N/A
| Market Performance vs. Industry/Classification (Health Information Services) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -7.52% | 52% | F | 40% | F | ||
| Dividend Return | 52.63% | 60% | D- | 84% | B | ||
| Total Return | 45.11% | 77% | C+ | 83% | B | ||
| Trailing 12 Months | |||||||
| Capital Gain | -8.89% | 47% | F | 34% | F | ||
| Dividend Return | 51.85% | 60% | D- | 84% | B | ||
| Total Return | 42.96% | 76% | C+ | 77% | C+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -13.62% | 42% | F | 17% | F | ||
| Dividend Return | -13.54% | 39% | F | 16% | F | ||
| Total Return | 0.08% | 29% | F | 5% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 18.38% | 82% | B | 69% | C- | ||
| Risk Adjusted Return | -73.66% | 32% | F | 13% | F | ||
| Market Capitalization | 1.65B | 87% | B+ | 64% | D | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
